07 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
Life Science Intelligence, July 2012
This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in July 2012.
All companies include technology, market(s), key executive, and contact information.
Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies
Brief Technology Descriptions For Companies Covered
- Fatty acid synthase (FASN) inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, for the treatment of chronic hepatitis C virus (HCV) and pancreatic, prostatic, breast, and colorectal tumors
- A custom fit, rehabilitative body suit that offers instantaneous back pain relief, trains and conditions the body to prevent or rehabilitate from back injuries, and increases the overall long-term health of the spine
- Biomaterial and regenerative medicine products for ophthalmological applications: ologen(R) Collagen Matrix, BioCornea, and Biolens
- First-in-class, small molecule compounds that successfully manage and treat chronic pain, by inhibiting P2X3 receptors
- Biomaterials for post-surgical adhesion prevention, scar prevention, wound care, and tissue reconstruction
- Micro-catheter platform that uses a proprietary microfluidic design for the delivery of drug/active molecules directly to the central nervous system for the treatment of difficult/chronic neurological conditions
- Protein therapeutics with extremely high target binding specificity for the treatment of cancer and immune-mediated diseases
- An antibody that blocks the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches
- Drugs for the treatment of depression, anxiety, epilepsy, pain, glaucoma, spasticity, and a variety of other CNS-related conditions
- Nanopharmaceuticals optimized to make drugs more effective and with fewer side effects
- Ocular microinjection platform for non-surgical, targeted delivery of drugs and proteins into the suprachoroidal space
- Biology and chemistry platforms for the development of small molecule drugs to stop Alzheimer's disease and other CNS-related conditions
- New generation of fully recombinant, protease-activated monoclonal antibodies that can achieve unprecedented levels of tissue-specific targeting
- A recombinant protein to treat X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder that can be life-threatening
- Minimally invasive, image-guided breast biopsy and tissue removal technologies
- Products that support transcatheter interventions for the heart
- Non-invasive series of genetic tests, designed to offer valuable insights into the biology of patients with mood disorders and to support the development of personalized medicine
- New avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA to treat a wide range of diseases, including cancer, fibrosis, inflammation, and infectious and degenerative diseases
- Diagnostic tests for the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury, often followed by life-long disability
- A device that enables surgeons to check for remaining cancer cells at the tumor site, immediately following surgical removal of the tumor
- The first vaccine to demonstrate efficacy in reducing the mortality of otherwise highly lethal bloodstream infections due to either Candida or S. aureus (including MRSA)
- Drugs to improve health for patients by modulating disease-associated long non-coding RNA (lncRNA), thereby restoring normal expression of individual targeted genes
- Neuromonitoring devices to prevent nerve damage in all types of surgical procedures
- Novel technology for the treatment of acne
- Fully synthetic and targeted vaccines that induce an antigen-specific immune activation or an antigen-specific immune tolerance for therapeutic and prophylactic applications
- Technology that will allow hospitals to consolidate the multiple types of infusion pumps used throughout their organization into a single type of device
- A laser procedure that removes the brown pigment (melanin) from the top layer of the iris, in order to change human eye color (to blue) permanently
- Decision support software, integrated with vital sign monitoring equipment in hospital ICUs/EDs, to provide novel insights into a patient's current status and future trajectory
- Revolutionary topical antifungal with: exceptional potency, the ability to penetrate the nail, a dual mode of action, and exemplary safety profile
- Unique diagnostic and monitoring technologies:
1-"Smart Optic Capillaroscope" for non-invasive diagnostics of early disorders in the smallest vessels-capillaries
2-"Hemodynamic Lab" for simultaneous diagnostics of the whole vascular system
3-"Meteolaboratory with Feedback Effect" for controlling influence of meteorological factors on the human organism
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
